SOPHiA GENETICS Aktie
| 3,31USD | -0,10USD | -2,93% |
WKN DE: A3CVT8 / ISIN: CH1125843347
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 70,99 |
| Marc. A. A. A. L Coucke, MBA | 10,70 |
| Generation Investment Management LLP | 10,39 |
| Generation Investment Management LLP | 10,39 |
| aMoon Ventures Y Sh Ltd. | 7,25 |
| Balderton Capital (UK) LLP | 5,14 |
| Jurgi Camblong, PhD, EMBA | 3,76 |
| Banque Pictet & Cie SA | 3,43 |
| Akre Capital Management LLC | 3,42 |
| Crédit Suisse Fund Management SA | 3,40 |
| CS Invt. Fds. 2 - (Lux) Digital Health Equity Fund | 3,37 |
| Principal Global Investors LLC | 2,23 |
| Alta Wealth Advisors LLC | 2,16 |
| Jennison Associates LLC | 1,85 |
| General Electric Co. (Investment Company) | 1,70 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 518 | 466 | 449 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,08 | 0,10 | 0,14 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 34 | 110 | 283 | 196 | 148 |
| Summe Anlagevermögen | 18 | 22 | 37 | 48 | 58 |
| Summe Aktiva | 52 | 132 | 320 | 244 | 206 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 8 | 7 | 13 | 17 | 19 |
| Summe Fremdkapital | 29 | 32 | 45 | 44 | 55 |
| Summe Eigenkapital | 22 | 101 | 275 | 200 | 151 |
| Summe Passiva | 52 | 132 | 320 | 244 | 206 |
Adresse
| La Piece 12, 1025 Rolle | |
| Telefon | +41 (21) 694-10-60 |
| Internet | http://www.sophiagenetics.com |
Management
|
Abhimanyu Verma
Chief Technology Officer |
|
Daan G. M. van Well
Executive VP, Chief Legal & Compliance Officer |
|
Didier Hirsch
Independent Non-Executive Director |
|
George A. Cardoza
Chief Financial Officer |
|
Jean-Michel Yves Sylvain Cossery
Independent Director |
|
Jurgi Camblong
Chief Executive Officer & Director |
|
Kathy L. Hibbs
Non-Executive Director |
|
Kellen Sanger
Investor Contact |
|
Ken Freedman
Chief Revenue Officer |
|
Kevin Puylaert
Vice President & Managing Director-EMEA |
|
Manuela da Silva Valente
Chief People Officer & Senior Vice President |
|
Peter Casasanto
Chief BioPharma Officer |
|
Philippe Menu
Executive VP, Chief Medical & Product Officer |
|
Ross Muken
President |
|
Tomer Berkovitz
Independent Non-Executive Director |
|
Troy M. Cox
Chairman |
|
Vincent Ossipow
Independent Non-Executive Director |
|
Zhenyu Xu
Chief Scientific Officer & Senior Vice President |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
